Bevacizumab is a vascular endothelial growth factor-A-specific angiogenesis inhibitor indicated as an adjunct to chemotherapy for the treatment of several types of cancer. Hypertension is commonly observed during bevacizumab treatment, and high-grade toxicity can limit therapy and lead to other cardiovascular complications. The factors that contribute to interindividual variability in blood pressure response to bevacizumab treatment are not well understood. In this review, we outline research efforts to understand the mechanisms and pathophysiology of hypertension resulting from bevacizumab treatment. Moreover, we highlight current knowledge of the pharmacogenetics of bevacizumab-induced hypertension, which may be used to develop strategies to prevent or minimize this toxicity.
Introduction
Bevacizumab (Avastin®, Genentech/Roche) is an angiogenesis inhibitor that is approved in the United States for the treatment of patients with metastatic colorectal cancer, advanced nonsquamous nonsmall cell lung cancer, metastatic renal cell carcinoma, recurrent glioblastoma, advanced cervical cancer, and platinum-resistant ovarian cancer (Ferrara & Adamis, 2016) . It is also approved for treatment of metastatic breast cancer in the European Union and other non-U.S. countries and was approved for this indication in the U.S. between 2008 and 2011. Bevacizumab is typically administered intravenously in the range of 5-15 mg/kg every 2 or 3 weeks (Genentech, Inc., 2016) . The addition of bevacizumab to standard chemotherapy regimens in the approved indications has been shown to significantly increase overall survival (OS), progression-free survival (PFS), and/or overall response rate (Ferrara & Adamis, 2016) .
Bevacizumab is a recombinant humanized monoclonal immunoglobulin (Ig) G1 antibody that binds to all isoforms and bioactive proteolytic fragments of human vascular endothelial growth factor-A (VEGF), which is essential for both normal and tumor angiogenesis. The antibody contains human framework regions with mutagenized murine-counterpart residues in six complementarity-determining regions (Ferrara, Hillan, Gerber, & Novotny, 2004) . By neutralizing VEGF, bevacizumab prevents the activation of VEGF tyrosine kinase receptors VEGFR1 and VEGFR2 on endothelial cells (Fig. 1) . The anti-tumor effect of bevacizumab is primarily attributed to the inhibition of VEGFR2-mediated angiogenesis (Ferrara et al., 2004) , slowing the growth of new blood vessels and effectively cutting off a tumor's supply of oxygen and nutrients. Inhibition of VEGF signaling also improves delivery of cytotoxic drugs by lowering tumor interstitial fluid pressure and by reducing the number of non-functional tumor blood vessels.
The most serious adverse effects of bevacizumab are gastrointestinal perforations, surgery and wound healing complications, and hemorrhage (Genentech, Inc., 2016) . Other common major adverse drug reactions include thromboembolism, proteinuria, and hypertension (HTN). HTN, a persistent elevation of arterial blood pressure (BP), is generally asymptomatic, but unmanaged HTN can lead to cardiovascular complications. Rare cases of hypertensive crisis with encephalopathy (Glusker, Recht, & Lane, 2006; Ozcan, Wong, & Hari, 2006) and subarachnoid hemorrhage (Baizabal-Carvallo, Alonso-Juárez, & Salas, 2010; Dissanayake, Ramakonar, & Lind, 2015; Zand, Kazemi, Barr, & Afshani, 2012) have also been reported for bevacizumab.
Here, we review the clinical presentation of bevacizumab-induced HTN and outline proposed mechanisms and biomarkers of this toxicity that have been discovered through pharmacological and genetic approaches.
http://dx.doi.org/10.1016/j.pharmthera.2017.08.012
Clinical presentation and management
Bevacizumab-induced HTN is commonly assessed on a scale of 1-5 as defined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) (National Cancer Institute, 2010), with grade 3-4 considered as high-grade HTN (Supplementary Table 1) . It should be noted that the definitions of grades 1-4 hypertension have changed with each version of the CTCAE, which requires consideration when comparing incidence rates and biomarker studies from different periods. HTN of all grades has been observed in up to 36% of patients treated with bevacizumab (Zhu, Wu, Dahut, & Parikh, 2007) . The reported incidence of high-grade HTN ranges from 1.8 to 22% (Ranpura, Pulipati, Chu, Zhu, & Wu, 2010) , with up to 1% of events being grade 4 (European Medicines Agency, 2017). In a meta-analysis of twenty phase II and phase III clinical trials, bevacizumab was reported to increase the risk of high-grade HTN by up to 5.28-fold (Ranpura et al., 2010) . Similar findings have been reported in other meta-analyses of trials of breast cancer (Cortes et al., 2012) and colorectal cancer (Loupakis et al., 2010) and across multiple indications (Zhu et al., 2007) .
The time to BP elevation upon receiving bevacizumab varies but is frequently observed within the first cycle of therapy (Maitland et al., 2010) . The toxicity appears to be dose-dependent, with a reported 7.5-fold increase in all-grade HTN risk in patients treated with high-dose (≥ 10 mg/kg) bevacizumab compared to a 3-fold increase in patients receiving low-dose (< 10 mg/kg) bevacizumab (Zhu et al., 2007) . In the same meta-analysis, the development of grade 3 HTN was observed in 8.7% of low-dose patients and 16.0% of high-dose patients. Development of HTN has also been associated with cumulative dose of bevacizumab (Feliu et al., 2015; Mir et al., 2011; Slusarz, Merker, Muzikansky, Francis, & Plotkin, 2014) , while other studies have demonstrated no dose effect (Hurwitz et al., 2013) . Regardless, high-grade HTN is still consistently observed at low doses (Hurwitz et al., 2013; Ranpura et al., 2010; Zhu et al., 2007) .
HTN also occurs during treatment with other VEGF pathway inhibitors (Maitland et al., 2010) , including aflibercept, a soluble decoy receptor that binds VEGF, and small molecule VEGF receptor tyrosine kinase inhibitors (TKI) such as sunitinib, sorafenib, pazopanib, axitinib, regorafenib, and cediranib. The frequency of all-grade HTN during treatment with VEGFR TKIs ranges from 15 to 67%, with a greater incidence observed during treatment with more potent inhibitors such as axitinib, regorafenib, and cediranib, where incidence of grade 3-4 HTN has been reported as high as 43% (Brinda, Viganego, Vo, Dolan, & Fradley, 2016) . The correlation of potency and HTN incidence suggests that HTN is primarily an on-target effect of VEGF inhibition.
Baseline clinical risk factors for VEGF inhibitor-induced HTN have yet to be established but preexisting HTN has been consistently shown to correlate directly with the development of treatment-related HTN (Hamnvik et al., 2015; Isobe et al., 2014; Wicki et al., 2014) . Age (≥ 60 years) and body mass index (≥ 25) have also been associated with anti-VEGF therapy-induced BP elevation (Hamnvik et al., 2015) . Other risk factors may include diabetes mellitus or high fasting glucose levels, preexisting or family history of cardiovascular disease, dyslipidemia, renal disease, subclinical organ damage, and cigarette smoking (Maitland et al., 2010) . Tumor type has also been suggested to have a role, with the highest risk of bevacizumab-induced HTN being reported in patients with renal cell carcinoma and breast cancer Ranpura et al., 2010) .
All patients on bevacizumab treatment are recommended to have BP monitored every two to three weeks. Patients who develop HTN or a significant rise in BP from baseline are recommended to initiate antihypertensive therapy, have current antihypertensive therapy titrated to better control, or have another agent added (Maitland et al., 2010) . Early initiation of antihypertensive therapy has been shown to reduce complications, even in life-threatening cases of encephalopathy (Seet & Rabinstein, 2012) , and to prevent or minimize HTN while continuing bevacizumab treatment (Izzedine et al., 2009; Langenberg et al., 2009) . Bevacizumab is temporarily suspended in patients with uncontrollable severe HTN and discontinued in the event of hypertensive crisis or hypertensive encephalopathy, with no recommended dose reductions (Genentech, Inc., 2016) . Upon discontinuation of bevacizumab, BP typically returns to pre-treatment levels (Maitland et al., 2010) .
Angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, beta blockers, and calcium channel blockers are all commonly used to treat angiogenesis inhibitor-induced HTN (Maitland et al., 2010) . No specific antihypertensive agent provides superior control of bevacizumab-induced HTN, though different classes have been proposed or recommended against as first-line treatment, primarily for other related effects. For example, ACE inhibitors are recommended for treatment of proteinuria (also induced by bevacizumab) (Dincer & Altundag, 2006) , while there is caution against use of the calcium channel blocker nifedipine, which has been shown to induce VEGF secretion (Izzedine et al., 2009 ). Long-acting oral nitrates have also been reported to successfully restore BP to baseline levels in patients with HTN refractory to combination treatment with ACE inhibitors and calcium channel blockers (Dirix, Maes, & Sweldens, 2007; Kruzliak, Kovacova, & Pechanova, 2013) . Fig. 1 . VEGF signaling and inhibition by bevacizumab. Vascular endothelial growth factor (VEGF) receptors are primarily expressed by endothelial cells. VEGFA binds both VEGFR1 and VEGFR2, although VEGFA-mediated angiogenesis is primarily through VEGFR2, while VEGFR1 functions primarily as a decoy receptor for VEGFA. Placental growth factor (PlGF) and VEGFB bind selectively to VEGFR1, and VEGFC and VEGFD bind to VEGFR3, a key regulator of lymphangiogenesis. Neuropilin co-receptors NRP1 and NRP2 also regulate VEGFR signaling. Binding of VEGF by bevacizumab prevents VEGFA-activated receptor signaling.
Pathophysiological mechanisms

Decreased vasodilation
The prevailing hypothesis for the mechanism of bevacizumab-induced HTN is an increase in vascular tone due to inhibition of VEGFmediated vasodilation. Direct administration of VEGF has been shown to induce vasorelaxation and lower BP (Henry et al., 2003 (Henry et al., , 2001 Horowitz et al., 1997) . Bevacizumab inhibited VEGF-induced vasodilation, measured by outer vessel diameter, in pig retinal arterioles (Su, Cringle, McAllister, & Yu, 2012) , and local administration of bevacizumab in human subjects rapidly decreased endothelium-dependent vasodilation (Thijs et al., 2013) . Thus, inhibition of VEGF signaling and decreased endothelium-dependent vasodilation may result in overall vascular resistance and the development of HTN.
VEGF signaling through VEGFR2 promotes vascular permeability and vasodilation (Ferrara, Gerber, & LeCouter, 2003; Li et al., 2002) in endothelial cells via the downstream release of the vasodilator molecules nitric oxide (NO), produced by endothelial nitric oxide synthase (eNOS) (Bouloumié, Schini-Kerth, & Busse, 1999; Hood, Meininger, Ziche, & Granger, 1998) , and prostacyclin (Neagoe, Lemieux, & Sirois, 2005; Wheeler-Jones et al., 1997) , generated from cyclooxygenasecatalyzed arachidonic acid metabolism (Fig. 2) . NO and prostacyclin act in a paracrine fashion on adjacent vascular smooth muscle cells to stimulate signaling that ultimately results in vasorelaxation (Robinson, Khankin, Karumanchi, & Humphreys, 2010) . Addition of bevacizumab to human umbilical vein endothelial cells has been shown to reduce VEGFR2 phosphorylation (Lee et al., 2007) and decrease NO production (Wang, Fei, Vanderlaan, & Song, 2004) . Administration of an anti-VEGFR2 antibody in mice resulted in a rapid rise in BP as well as reduction of eNOS and neuronal NO synthase expression in the kidney (Facemire, Nixon, Griffiths, Hurwitz, & Coffman, 2009) .
While many studies have shown a decrease in eNOS activity and NO production during VEGF pathway inhibition, others have shown that both NO-dependent and NO-independent vasodilation are reduced (Lankhorst, Kappers, van Esch, Danser, & van den Meiracker, 2014) . Therefore, other endothelial signaling pathways adjacent to VEGF signaling have been proposed contributors to a decrease in vasodilation. One such pathway focuses on the action of endothelin-1 (ET-1). ET-1 exerts its effects on neighboring vascular endothelial and smooth muscle cells via activation of ET A and ET B receptors (Vignon-Zellweger, Heiden, Miyauchi, & Emoto, 2012) . In smooth muscle, where both ET A , and activation of the PI3K-Akt pathway lead to phosphorylation and activation of endothelial nitric oxide synthase (eNOS) and generation of nitric oxide (NO). PKC also activates the Ras/MEK/ERK pathway, which in turn upregulates cytosolic phospholipase A2 (cPLA 2 ). cPLA 2 releases arachidonic acid (AA) from phospholipids, which is acted on by cyclooxygenases (COX-1/COX-2) to generate prostaglandin H 2 (PGH 2 ), which is then converted to prostacyclin (PGI 2 ) by prostacyclin synthase (PGIS). NO and PGI 2 diffuse to adjacent smooth muscle cells, where NO activates soluble guanylate cyclase (sGC), leading to cGMP synthesis. PGI 2 binds to prostacyclin receptors (IP), which activate adenylyl cyclase (AC) and increase cAMP synthesis. cGMP and cAMP lead to decreased intracellular Ca 2 + concentrations, which induce vasorelaxation. and Therapeutics 182 (2018) 152-160 and ET B receptors are expressed, ET-1 acts as a vasoconstrictor, while in endothelial cells, which express only ET B receptors, ET-1 promotes vasodilation (Lankhorst, Kappers, van Esch, Danser, & van den Meiracker, 2013; Liu, Premont, Kontos, Huang, & Rockey, 2003; Vignon-Zellweger et al., 2012) . VEGF has been shown to influence ET-1 expression, though the relationship is not entirely understood. Plasma concentrations of ET-1 have been reported to increase following administration of the VEGFR TKI sunitinib in patients (Kappers et al., 2010) . Treatment of human microvascular endothelial cells with VEGF decreased ET-1 production (Star, Giovinazzo, Lamoureux, & Langleben, 2014) but has also been reported to induce ET-1 expression in bovine aortic endothelial cells and human umbilical vein endothelial cells (Matsuura, Yamochi, Hirata, Kawashima, & Yokoyama, 1998; Seol, Oh, & Kim, 2011) . Ongoing research is being conducted to elucidate the role of ET-1 in the onset of HTN during inhibition of VEGF signaling (Kappers et al., 2010 Lankhorst et al., 2014) .
Other sources of vascular resistance
While inhibition of VEGF-mediated vasodilation is the dominant hypothesis for the pathophysiology of bevacizumab-induced HTN, it has yet to be established as the sole cause of the toxicity. Other mechanisms proposed to contribute to bevacizumab-induced HTN include other sources of endothelial and vascular dysfunction. Microvascular rarefaction, or the reduction of capillary density, is a consequence of inhibiting VEGF (Baffert et al., 2006; Kamba et al., 2006) , which is required for endothelial cell survival (Gerber et al., 1998; Lee et al., 2007) . Decreased capillary density may lead to increased systemic vascular resistance and pressure in larger vessels. A rise in BP accompanied by a decrease in dermal capillary density has been observed after six months of bevacizumab treatment (Mourad, des Guetz, Debbabi, & Levy, 2008) . Arterial stiffness, possibly resulting from changes to extracellular matrix or matrix-interacting proteins, can also contribute to a systemic rise in BP (Safar, Levy, & Struijker-Boudier, 2003) . Increased vascular stiffness has been observed in patients treated with sorafenib (Veronese et al., 2006) . Oxidative stress and the production of abnormal levels of reactive oxygen species may also contribute to the development of HTN, possibly through reactive oxygen species-mediated apoptosis of endothelial cells (Case, Ingram, & Haneline, 2008) or excess oxidation of NO (Schulz, Jansen, Wenzel, Daiber, & Münzel, 2008) , decreasing its bioavailability for vasodilator tone.
Renal dysfunction
Alterations in renal function may also contribute to the development of bevacizumab-induced HTN. VEGF expression in kidney endothelial cells and podocytes is needed to maintain normal glomerular structure and filtration (Coultas, Chawengsaksophak, & Rossant, 2005) . Features of thrombotic microangiopathy were observed in bevacizumab-treated patients, and local genetic ablation of VEGF in kidney podocytes has been shown to lead to glomerular injury and elevated BP in mice (Eremina et al., 2008) . Renal changes may be influenced by downregulation of NO, which directly affects tubuloglomerular feedback, pressure natriuresis, and sodium homeostasis (Zou & Cowley, 1999) . Mice treated with a VEGFR2 inhibitor have a reduction of kidney eNOS and neuronal NOS expression and a shift in the pressurenatriuresis relationship (Facemire et al., 2009) . Similarly, administration of sunitinib in rats resulted in renal histological abnormalities and increased arterial pressure, and treatment of cultured human renal proximal tubular epithelial cells with sunitinib reduced VEGF-induced eNOS protein expression (Gu et al., 2009 ). Activation of the renin angiotensin system has also been implicated, though experimental and clinical evidence have mostly disputed this hypothesis (Facemire et al., 2009; Lankhorst et al., 2013) .
Clues from other forms of hypertension
Bevacizumab-induced HTN is a type of secondary HTN, or HTN related to a specific known etiology, though the exact mechanisms by which bevacizumab causes HTN (Fig. 3) remain unclear. Other common causes of secondary HTN include obstructive sleep apnea, renal parenchymal disease, renal artery stenosis, primary aldosteronism, thyroid disease, Cushing's syndrome, pheochromocytoma, and coarctation of the aorta (Rimoldi, Scherrer, & Messerli, 2014) . Monogenic syndromes are also considered as secondary HTN and have been mapped to at least 
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Pharmacology and Therapeutics 182 (2018) 152-160 25 genetic loci (Padmanabhan, Caulfield, & Dominiczak, 2015) . Many of these highly penetrant rare mutations affect renal salt handling or mineralocorticoid activity, which regulate electrolyte balance and fluid volume. Primary HTN is elevated BP of unknown etiology and affects approximately one billion adults worldwide and accounts for 9.4 million deaths each year (World Health Organization, 2013) . Studies of primary HTN have collectively accumulated evidence that BP regulation entails complex and dynamic interactions among multiple tissue and organ systems. Dysregulation of sodium and fluid balance and vasomotor tone have been implicated in the development of primary HTN, with environmental and genetic factors perturbing multiple physiological mechanisms in the heart and blood vessels, kidney, and neuroendocrine system that contribute to both functions (Oparil, Zaman, & Calhoun, 2003) . While the mechanisms of drug-induced HTN may differ from those causing primary HTN, the pathophysiological and genetic factors contributing to both types may overlap, and any factors underlying primary HTN may be exacerbated by drug treatment. Thus, an understanding of primary HTN is necessary to formulate questions related to bevacizumab-induced HTN.
Family and twin studies estimate BP to be moderately heritable (30-50%) (Levy et al., 2007; Miall & Oldham, 1963; Snieder et al., 2000) , and HTN is 2.4 times more common in men with two hypertensive parents , suggesting that BP regulation is largely influenced by genetics. (Ehret et al., 2016; Hoffmann et al., 2017; Liu et al., 2016; Surendran et al., 2016; Warren et al., 2017) have nearly doubled that count. Despite numerous large-scale studies, the genetic architecture of primary HTN is still poorly understood. A majority of identified SNPs are in noncoding regions with unknown functional effects, and identifying causal variants and mechanisms remains a major challenge. All identified common variants together still only explain < 5% of the total variance in BP (Munroe, Barnes, & Caulfield, 2013) , leaving much of the genetic contribution to BP variability unexplained. More recently, studies of primary HTN using sequencing methods or exome arrays have been performed to identify rare and low frequency variants contributing to variability in BP (Ji et al., 2008; Liu et al., 2016; Morrison et al., 2014; Surendran et al., 2016; Yu et al., 2016) . Future sequencing initiatives in substantially larger sample sizes may uncover even more variants associated with primary HTN that may inform additional pathophysiological mechanisms contributing to both primary and secondary forms of the disease.
Pharmacogenetics
While there already exists supporting evidence for the mechanism of bevacizumab-induced HTN, it remains unknown why such great interindividual variability in BP elevation exists among patients treated with bevacizumab. Both environmental and genetic factors may influence the risk and severity of bevacizumab toxicity.
Bevacizumab pharmacokinetics
The pharmacokinetics of bevacizumab are well-described by a linear two-compartment model (Lu et al., 2008) . Bevacizumab elimination relies on proteolytic catabolism throughout the body and is also regulated by FcRn-receptor-mediated recycling (European Medicines Agency, 2017). Body weight and gender explain most of the interindividual variability in bevacizumab clearance and volume (Lu et al., 2008) , and thus bevacizumab is administered on a mg/kg basis. Serum albumin, alkaline phosphatase (ALP), serum aspartate aminotransferase (AST), and tumor burden have also been reported to affect clearance rates (Kazazi-Hyseni, Beijnen, & Schellens, 2010) . None of these factors are expected to have a significant impact on unbound VEGF levels or efficacy (Lu et al., 2008) . Genetic variants affecting the binding affinities of VEGF (Panoilia et al., 2015) or FcRn (Kazazi-Hyseni et al., 2010) have been suggested to influence bevacizumab pharmacokinetics, but a significant correlation has yet to be established.
Functional variation in VEGF and VEGFR2
Studies of variation in bevacizumab pharmacodynamics also have not yet yielded any validated markers to predict bevacizumab efficacy or toxicity. Attempts to identify tumor-derived biomarkers have been unsuccessful (Schneider et al., 2008) . Because bevacizumab targets host-mediated angiogenesis, predictors of both efficacy and toxicity are likely to be host factors. In searching for genetic biomarkers of bevacizumab-induced HTN, prior studies have primarily focused on common functional SNPs in VEGFA and KDR, as these genes encode the most direct targets of bevacizumab, VEGF and VEGFR2. Several VEGFA polymorphisms located in the promoter and 5′ and 3′ untranslated regions are associated with differential VEGF expression and serum levels (Abajo et al., 2010; Awata et al., 2002; Chen et al., 2011; Koukourakis et al., 2004; Morita et al., 2013; Renner, Kotschan, Hoffmann, Obermayer-Pietsch, & Pilger, 2000; Steffensen, Waldstrøm, Brandslund, & Jakobsen, 2010) . Such polymorphisms include rs699947 [minor allele frequency (MAF) 0.49 in the 1000 Genomes Project (1000G) EUR population], rs833061 (MAF 0.49), rs1570360 (MAF 0.35), rs2010963 (MAF 0.30), and rs3025039 (MAF 0.12). Nonsynonymous functional variants in KDR are also commonly examined in relation to bevacizumab-induced HTN. rs2305948 (V297I, exon 7; MAF 0.08 in 1000G EUR) results in an amino acid change in the third Ig-like domain of VEGFR2, which is critical for binding of the VEGF ligand (Fuh, Li, Crowley, Cunningham, & Wells, 1998; Wang et al., 2007) . rs1870377 (Q472H, exon 11; MAF 0.23 in 1000G EUR) affects the fifth VEGFR2 Ig-like domain, which contains structural features that inhibit VEGFR2 signaling in the absence of VEGF (Tao, Backer, Backer, & Terman, 2001 ). rs34231037 (C482R; MAF 0.03 in 1000G EUR), which lies 28 bp downstream of rs1870377 in the same domain, has been associated with baseline serum VEGFR2 levels as well as changes in serum VEGFR2 levels in response to pazopanib (Maitland et al., 2015) . This mutation has been shown to induce ligand-independent constitutive VEGFR2 dimerization and activation (Sarabipour, Ballmer-Hofer, & Hristova, 2016) and to decrease the ability of VEGFR2 to activate VEGFR1 expression (Jinnin et al., 2008) . Collectively, these data support a role for abnormalities in VEGF and VEGFR2 function in altered basal VEGF signaling that influences bevacizumab sensitivity and highlight the complexity of mechanisms underlying this drug-induced toxicity phenotype.
Genetic studies of bevacizumab-induced hypertension
Previous studies of bevacizumab-induced HTN have identified significant associations between VEGFA and KDR SNPs and incidence of the toxicity (Table 1) . Schneider et al. identified associations between rs833061 and rs2010963 with incidence of grade 3-4 HTN in the ECOG-2100 trial of bevacizumab and first-line paclitaxel in patients with metastatic breast cancer (Schneider et al., 2008) . Jain et al. performed a meta-analysis of bevacizumab treated patients across six different trials and identified carriers of rs1870377 as having greater risk of developing grade 2+ HTN (Jain et al., 2010) . Etienne-Grimaldi et al. genotyped women with locally recurrent or metastatic breast cancer receiving bevacizumab-containing therapy and found a significant association between rs2010963 and all-grade HTN (Etienne-Grimaldi et al., 2011), though with the opposite direction of effect as reported by and Therapeutics 182 (2018) 152-160 Schneider et al. In bevacizumab-treated patients with metastatic colorectal cancer, Morita et al. identified rs699947 and rs833061 to be associated with early grade 2+ HTN (during the first two months of treatment) and rs699947and rs3025039 to be associated with grade 2 + HTN during the entire treatment period (Morita et al., 2013) ; the direction of effect for rs833061 agreed with that of Schneider et al.
Sibertin-Blanc et al. identified an association of rs3025039 with incidence of all-grade HTN in metastatic colorectal cancer patients (Sibertin-Blanc et al., 2015) , with a direction of effect that contradicts that in the Morita et al. study. Finally, Gampenrieder et al. found an association between rs2010963 and the incidence of bevacizumab-induced HTN in metastatic breast cancer patients (Gampenrieder et al., 2016) , with a direction of effect that agrees with Schneider et al. but not Etienne-Grimaldi et al.
More recent studies have expanded the set of examined genes beyond VEGFA and KDR. Lambrechts et al. tested 236 SNPs in VEGF pathway and HTN-related genes in a meta-analysis of six trials of bevacizumab treatment (Lambrechts et al., 2014) . No SNP surpassed the adjusted significance threshold, but SNPs in EGLN3, EGF, WNK1, and KDR had the strongest associations with all-grade HTN. Schneider et al. expanded their initial study to a GWAS of bevacizumab-treated breast cancer patients in ECOG-5103. Intronic SV2C SNP rs6453204 associated with high systolic BP in the discovery study and was validated for association with grade 3-4 HTN in a subset of ECOG-2100 patients (Schneider et al., 2014) . SV2C encodes a synaptic vesicle glycoprotein, and Schneider et al. postulate that the protein may influence BP through the release of catecholamines from adrenal chromaffin cells and production of aldosterone through adrenocortical connections with the adrenal medulla. rs1129660, a polymorphism in the autophagyrelated gene FIP200, associated with lower rate of grade 2-3 HTN in metastatic colorectal cancer patients (Berger et al., 2017) . The relation between FIP200 and HTN is unclear, but Berger et al. suggest that FIP200 genetic variants may influence vascular integrity.
Genetic associations with HTN toxicity have also been reported during treatment with VEGFR TKIs. SNPs in VEGFA, KDR, and NOS3 (eNOS) are associated with sunitinib-induced HTN (Eechoute et al., 2012; Garcia-Donas et al., 2011; Kim et al., 2012; van Erp et al., 2009) . Variants in genes encoding hepatic and renal drug metabolizing enzymes and transporters also associate with TKI toxicities (Diekstra, Swen, Gelderblom, & Guchelaar, 2016; Semeniuk-Wojtaś, Lubas, Stec, Szczylik, & Niemczyk, 2016) , though these are not expected to affect bevacizumab pharmacokinetics.
In summary, SNPs in VEGFA, KDR, SV2C, and FIP200 have been significantly associated with incidence of bevacizumab-induced HTN, and SNPs in EGLN3, EGF, and WNK1 have been modestly associated with the toxicity. However, the directions of effect for several of these findings are discordant, and no association has been replicated consistently across multiple studies or validated with mechanistic studies. Earlier CTCAE HTN grade 3 criteria had lower thresholds and relied primarily on subjective interpretation, which may result in differing case definitions and spurious associations in studies using CTCAE grades as the phenotype. Given the complexity of primary HTN, the genetic architecture contributing to bevacizumab-induced HTN is also likely to be polygenic. Therefore, further pharmacogenetic research, ideally with a more quantitative, standardized phenotype, is warranted in additional cohorts to extend these current findings. A meta-analysis across multiple studies is likely needed to overcome sample size limitations inherent in most clinical study populations. Aggregate effects and interactions of all clinical risk factors and reported risk variants on bevacizumab-induced HTN should also be examined in larger populations. Finally, functional studies are necessary to provide evidence for the involvement of any associated variants in the mechanism of bevacizumab-induced HTN.
Hypertension as a marker of bevacizumab efficacy
Clinical, radiological, and molecular markers have been examined to identify biomarkers or other surrogate markers to predict bevacizumab efficacy. Genetic markers, most of which consist of the VEGFA functional polymorphisms mentioned above, have been significantly associated with improved OS and PFS in several studies (de Haas et al., 2014; Eng et al., 2012; Jain et al., 2009; Lambrechts, Lenz, de Haas, Carmeliet, & Scherer, 2013) . However, few of these pharmacogenetic findings have had consistent results.
The relationship between bevacizumab-induced HTN and efficacy has also been examined, with the development of HTN being proposed as a pharmacodynamic marker for the inhibition of the VEGF signaling pathway (Maitland et al., 2006) . Multiple studies and meta-analyses have identified associations between bevacizumab-induced HTN and longer OS, PFS, or response rate (Cai et al., 2013; Chen, Sun, Ye, Weng, & Dai, 2014; Jubb & Harris, 2010; Mangoni, Woodman, Kichenadasse, Rowland, & Sorich, 2016) . The onset of bevacizumabinduced HTN with superior outcome was rigorously analyzed in a study of bevacizumab in combination with carboplatin and paclitaxel for the treatment of advanced non-small-cell lung cancer (ECOG 4599) (Dahlberg, Sandler, Brahmer, Schiller, & Johnson, 2010) . By implementing landmark analyses and adjusting for HTN as a time-varying covariate, the study demonstrated significantly improved OS and PFS in bevacizumab-treated patients with high BP compared to patients without high BP; this difference in outcome by BP status was non- (2017) a Minor allele frequency reported in 1000 Genomes Project EUR population.
M. Li, D.L. Kroetz Pharmacology and Therapeutics 182 (2018) 152-160 existent in patients who did not receive bevacizumab. However, other meta-analyses have found no consistent correlation between HTN and clinical benefit. In an analysis of seven phase III studies across multiple tumor types, Hurwitz et al. detected no association between early BP increase and PFS or OS (Hurwitz et al., 2013) . Similarly, Ranpura et al. found no significant correlation between the relative risks of high-grade HTN and the hazard ratios of PFS or OS in 20 studies of bevacizumab treatment (Ranpura et al., 2010) . If the development of HTN is indeed predictive of improved clinical outcomes, cases of high-grade HTN that would normally prompt discontinuation of bevacizumab treatment may instead warrant more aggressive treatment of HTN. Dose titration of bevacizumab while closely monitoring BP has been proposed to improve outcomes (Dewdney, Cunningham, Barbachano, & Chau, 2012) . Because bevacizumab-induced HTN is hypothesized to be an on-target drug effect, identification of genetic variants that influence both BP regulation and VEGF inhibition may enable prediction of both toxicity and efficacy prior to treatment.
Conclusion
HTN is commonly observed during bevacizumab treatment, and high-grade toxicity can limit therapy and lead to other cardiovascular complications. While many molecular mechanisms have been proposed to explain this adverse drug reaction, the factors that contribute to interindividual variability in BP response to bevacizumab treatment are still not well understood. Pharmacogenetic studies have identified variants associated with bevacizumab-induced HTN, and these variants require further replication and functional validation to establish their role in the toxicity of bevacizumab-based therapy. Additional research on the risk factors and mechanisms of bevacizumab-induced HTN is necessary to support the development of improved and novel strategies to treat bevacizumab-induced HTN and to minimize the number of patients impacted by this dose-limiting toxicity.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.pharmthera.2017.08.012.
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